Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

D. Goldsmith; A. Covic; M.G. Vervloet; M. Cozzolino; I. Nistor

doi:10.1093/ndt/gfv050

Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

D. Goldsmith, A. Covic, M.G. Vervloet, M. Cozzolino, I. Nistor

Nephrology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	698-700
Journal	Nephrology, Dialysis, Transplantation
Volume	30
Issue number	5
DOIs	https://doi.org/10.1093/ndt/gfv050
Publication status	Published - 2015

Access to Document

10.1093/ndt/gfv050

Cite this

@article{26e6008002874498897de3c789e8cf8e,

title = "Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement",

author = "D. Goldsmith and A. Covic and M.G. Vervloet and M. Cozzolino and I. Nistor",

year = "2015",

doi = "10.1093/ndt/gfv050",

language = "Undefined/Unknown",

volume = "30",

pages = "698--700",

journal = "Nephrology, Dialysis, Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

AU - Goldsmith, D.

AU - Covic, A.

AU - Vervloet, M.G.

AU - Cozzolino, M.

AU - Nistor, I.

PY - 2015

Y1 - 2015

U2 - 10.1093/ndt/gfv050

DO - 10.1093/ndt/gfv050

M3 - Article

C2 - 25928337

SN - 0931-0509

VL - 30

SP - 698

EP - 700

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

IS - 5

ER -